6.10
전일 마감가:
$6.22
열려 있는:
$6.69
하루 거래량:
4,853
Relative Volume:
0.20
시가총액:
$6.71M
수익:
-
순이익/손실:
$-57.11M
주가수익비율:
-0.4067
EPS:
-15
순현금흐름:
$-34.82M
1주 성능:
-13.84%
1개월 성능:
-5.13%
6개월 성능:
-31.46%
1년 성능:
-80.12%
아폴로믹스 Stock (APLM) Company Profile
APLM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APLM
Apollomics Inc
|
6.10 | 7.81M | 0 | -57.11M | -34.82M | -15.00 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
아폴로믹스 주식(APLM)의 최신 뉴스
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World
How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com
Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus
Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus
(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World
APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech
Apollomics Meets Nasdaq Compliance On Bid Price Requirement - Nasdaq
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges By Investing.com - Investing.com South Africa
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan
When the Price of (APLM) Talks, People Listen - Stock Traders Daily
Apollomics Inc trading halted, news pending - MSN
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com India
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence By Investing.com - Investing.com South Africa
아폴로믹스 (APLM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):